Reportlinker Adds Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Jan 04, 2010, 09:32 ET from Reportlinker

NEW YORK, Jan. 4 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0170505/Alzheimers-Disease-Therapeutics-and-Diagnostics-Global-Markets.html

THIS REPORT:

Focus on the background and the current state of disease-modifying and treatment-of-symptoms therapeutics, and the diagnostics global market segments

Provide global market data for 2008, estimates for 2009, and forecasts, with compound annual growth rates (CAGRS), through 2014

Discuss the increasingly difficult challenges that caregivers, families and the healthcare industry face as the number of patients climbs and the frustration with the lack of effective treatments grows

Review treatments in development and quantify the opportunities in the Alzheimer's disease market

Offer detailed company profiles and patent analyses.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

SCOPE OF REPORT 1

INTENDED AUDIENCE 2

METHODOLOGY 2

INFORMATION SOURCES 2

ANALYST CREDENTIALS 2

RELATED BCC REPORTS 2

BCC ONLINE SERVICES 3

DISCLAIMER 3

Chapter-2: SUMMARY

SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, THROUGH 2014 ($ MILLIONS) 4

SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2008-2014 ($ MILLIONS) 4

FORECAST SUMMARY 5

Chapter-3: OVERVIEW

DEFINITION AND MARKET STRUCTURE 6

WHAT IS ALZHEIMER'S DISEASE? 6

TABLE 1 U.S. ALZHEIMER'S PATIENTS, 2000-2050 (MILLIONS) 6

FIGURE 1 U.S. ALZHEIMER'S PATIENTS, 2000-2050 (MILLIONS) 7

Role of the Cholinergic System 7

Role of Beta-Amyloid Protein 8

Behavioral Manifestations of AD 9

INCIDENCE AND PREVALENCE 9

TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2009-2050 (MILLIONS) 9

TABLE 3 PERCENT POPULATION OVER 65, BY REGION (%) 10

TABLE 4 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS) 10

FIGURE 2 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS) 10

TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET 11

FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET (%) 11

TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%) 12

STAGES OF ALZHEIMER'S DISEASE 12

Stages of Alzheimer's ... (Continued) 13

DIAGNOSIS 14

TABLE 7 DIAGNOSTIC TESTS 15

How Accurate are the Screening Tests? 16

KEY EVENTS 17

PATENT EXPIRATIONS 17

NEW PRODUCT LAUNCHES 18

PRICING 18

KEY MARKETS 18

TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, THROUGH 2014 ($ MILLIONS) 18

FIGURE 4 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2008-2014 ($ MILLIONS) 19

MARKET SIZE AND KEY PLAYERS 19

THERAPEUTICS 20

TABLE 9 EXISTING TREATMENTS: ALZHEIMER'S DISEASE 20

TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM-ADDRESSING ALZHEIMER'S DISEASE, BY TYPE, 2002-2009 ($ MILLIONS) 20

TABLE 10 (CONTINUED) 21

TABLE 11 GLOBALMARKET FOR ALZHEIMER'S DRUG CLASSES BY GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN), 2009 ESTIMATED ($ MILLIONS) 21

TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER'S DISEASE 21

TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER'S DISEASE, 2008 22

TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%) 22

TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE STATE (%) 23

TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) 23

TABLE 17 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, THROUGH 2014 ($ MILLIONS) 24

FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, 2007-2014 ($ MILLIONS) 24

TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS, THROUGH 2014 ($ MILLIONS) 24

TABLE 18 (CONTINUED) 25

FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA, 2008 (%) 25

Key Players 26

TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND COGNITION (%) 26

TABLE 20 MARKETED TREATMENTS: ALZHEIMER'S DISEASE 26

TABLE 20 (CONTINUED) 27

Drivers 27

Issues and Challenges 27

IMAGING AND DIAGNOSTICS 27

Current Use in Alzheimer's Disease 27

Current Use in ... (Continued) 28

Diagnostic Testing Segments 29

Imaging 29

TABLE 21 IMAGING MARKET, 2008 ($ MILLIONS) 30

FIGURE 7 IMAGING MARKET, 2008 ($ MILLIONS) 30

Standardization Needed 30

Diagnostics 31

Novel Imaging Agents 32

Opportunities for Biomarkers in AD 33

TABLE 22 BIOMARKERS FOR ALZHEIMER'S DISEASE 34

TABLE 22 (CONTINUED) 35

TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, THROUGH 2014 ($ MILLIONS) 36

FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, 2008-2014 ($ MILLIONS) 36

Opportunities for ... (Continued) 37

Opportunities for ... (Continued) 38

TABLE 24 U.S. CLINICAL TRIAL MARKET FOR BIOMARKERS BY PHASE--NUMBER OF TRIALS, PATIENTS, BIOMARKER PATIENTS, COST PER TEST, MARKET SIZE, 2008 39

TABLE 25 CLINICAL TRIAL MARKET FOR BIOMARKERS BY GEOGRAPHICAL REGION, 2008 ($ MILLIONS) 39

Testing Hypotheses 40

Diagnostic Tests 40

Diagnostic Tests (Continued) 41

Key Players 42

Agilent Technologies 42

Bioscan 42

Capintec Inc. 43

Digirad Corporation 43

Gamma Medica-Ideas 43

GE Healthcare 44

Hitachi Medical Systems America Inc. 44

Nymox 44

OptoSonics Inc. 45

Philips Healthcare 46

Positron Corp. 46

Siemens Healthcare 47

Spectrum Dynamics Ltd. 47

Toshiba Medical Systems 48

UltraSPECT Ltd. 48

VisEn Medical Inc. 48

Zecotek Imaging Systems 49

Drivers 49

Issues and Challenges 49

SWOT ANALYSIS 50

TABLE 26 SWOT ANALYSIS OF EXISTING ALZHEIMER'S DISEASE MARKET AND PLAYERS 50

Chapter-4: TECHNOLOGIES AND APPLICATIONS

COMMON MECHANISMS OF ACTION 51

CHOLINESTERASE INHIBITORS 52

TABLE 27 CHOLINESTERASE INHIBITORS 52

TABLE 28 PRODUCT SIDE EFFECT COMPARISON (%) 53

FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%) 53

TABLE 29 VACCINES 54

TABLE 30 ANTI-OXIDANTS 54

NMDA ANTAGONISTS 54

TABLE 31 NMDA ANTAGONISTS 55

NICOTINICS 55

TABLE 32 NICOTINIC ACETYLCHOLINE ANTAGONISTS 56

CALCINEURINS 56

TABLE 33 CALCINEURINS 56

GABA MODULATORS 56

TABLE 34 ANTI-EPILEPTIC/GABA MODULATORS 57

HORMONES 57

TABLE 35 HORMONES 58

OTHER THERAPEUTIC MECHANISMS 58

TABLE 36 OTC TREATMENTS/NATURAL PRODUCTS 59

IMAGING AND DIAGNOSTICS--MODALITIES AND APPLICATIONS 59

IMAGING AND DIAGNOSTICS...(CONTINUED) 60

NUCLEAR MEDICINE 61

Positron Emission Tomography (PET) 61

Single Photon Emission Computed Tomography (SPECT) 62

Gamma Cameras 63

CT (COMPUTED TOMOGRAPHY) 63

DEXA 63

MRI (MAGNETIC RESONANCE IMAGING) 64

ULTRASOUND 65

X-RAY 65

FUSION IMAGING 66

PET/CT 66

SPECT/CT 67

SPECT-CT in Cardiology 67

SPECT-CT in General Nuclear Medicine 68

SPECT-CT in Neurology 68

DIAGNOSTIC IMAGING IN ALZHEIMER'S 69

DISEASE-MODIFYING VS. TREATMENT OF SYMPTOMS 70

SYMPTOMATIC RELIEF--LIFE-CYCLE MANAGEMENT OF EXISTING PRODUCTS 71

OTHER DRUGS TARGETING SYMPTOMATIC RELIEF 71

DRUG RE-PURPOSING 72

GENERICS 72

Chapter-5: WORLDWIDE INDUSTRY STRUCTURE

GROWTH DRIVERS 73

AGING POPULATION 73

OFF-LABEL USE 74

UNDERSTANDING OF MECHANISMS 75

Transcranial Magnetic Stimulation 76

Genetic Modifications 76

GROWTH OBSTACLES 77

UNDERSTANDING OF MECHANISMS 77

TABLE 37 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 78

CO-MORBID DISEASE STATES 78

KEY COMPETITIVE FACTORS 78

PRODUCT LAUNCH 79

LIFE CYCLE MANAGEMENT 79

PAYORS 79

Payors (Continued) 80

INTERNATIONAL ASPECTS 81

TABLE 38 PERCAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY, THROUGH 2006 ($ MILLIONS) 82

INTERNATIONAL ASPECTS (CONTINUED) 83

Chapter-6: LEGISLATION AND REGULATORY ENVIRONMENT

VALIDATED TARGETS 84

LACK OF BIOMARKERS 84

TRANSLATIONAL MEDICINE 85

REIMBURSEMENT 86

Chapter-7: RELATED DEALS AND PARTNERSHIPS

APPROACH 87

DIAGNOSTICS DEALS 88

OVERALL ACTIVITY 88

TABLE 39 RELATED DEALS AND PARTNERSHIPS, 2004-2009 89

TABLE 39 (CONTINUED) 90

TABLE 39 (CONTINUED) 91

Chapter-8: PIPELINE

PIPELINE 92

TABLE 40 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS, BY PHASE 93

TABLE 40 (CONTINUED) 94

TABLE 40 (CONTINUED) 95

TABLE 40 (CONTINUED) 96

TABLE 40 (CONTINUED) 97

TABLE 40 (CONTINUED) 98

FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS: NUMBER OF PROGRAMS AT EACH CLINICAL PHASE 98

FIGURE 10 (CONTINUED) 99

Chapter-9: TRENDS AND CHALLENGES

AWARENESS OF ALZHEIMER'S 100

DISEASE PATHWAYS BEING ELUCIDATED 100

MANY PROGRAMS IN DEVELOPMENT 101

TABLE 41 SOME NOT-FOR-PROFIT ORGANIZATIONS AND CONSORTIA IN THE AD AREA 101

MANY PROGRAMS IN DEVELOPMENT (CONTINUED) 102

TABLE 42 INVESTMENT IN ALZHEIMER'S DISEASE COMPANIES 103

Chapter-10: OUTLOOK

A VARIETY OF APPROACHES IN RESEARCH 104

MANY PROGRAMS IN DEVELOPMENT 105

Chapter-11: PATENT ANALYSIS

TABLE 43 KEY PATENT EXPIRY--ALZHEIMER'S THERAPEUTICS, BY CATEGORY 106

TABLE 44 MAJOR U.S. PATENT HOLDERS/FILERS IN ALZHEIMER'S THERAPEUTICS AND TECHNOLOGIES 107

TABLE 45 PATENT APPLICATIONS (U.S.) 107

TABLE 45 (CONTINUED) 108

TABLE 45 (CONTINUED) 109

TABLE 45 (CONTINUED) 110

TABLE 45 (CONTINUED) 111

TABLE 45 (CONTINUED) 112

TABLE 45 (CONTINUED) 113

TABLE 45 (CONTINUED) 114

TABLE 45 (CONTINUED) 115

TABLE 45 (CONTINUED) 116

TABLE 45 (CONTINUED) 117

TABLE 45 (CONTINUED) 118

TABLE 45 (CONTINUED) 119

TABLE 45 (CONTINUED) 120

TABLE 46 ISSUED PATENTS (U.S.) 120

TABLE 46 (CONTINUED) 121

TABLE 46 (CONTINUED) 122

TABLE 46 (CONTINUED) 123

TABLE 46 (CONTINUED) 124

TABLE 46 (CONTINUED) 125

TABLE 46 (CONTINUED) 126

TABLE 46 (CONTINUED) 127

TABLE 46 (CONTINUED) 128

TABLE 46 (CONTINUED) 129

TABLE 46 (CONTINUED) 130

TABLE 46 (CONTINUED) 131

Chapter-12: COMPANY PROFILES

ABLYNX 132

ACCERA, INC. 132

ACUMEN PHARMACEUTICALS 133

AFFIRIS AG 133

AFFITECH AS 134

ALLON THERAPEUTICS (FKA NEURODISCOVERY) 134

ALZHYME PTY 135

ASTELLAS 135

ASTRAZENECA 136

ATHENA DIAGNOSTICS (THERMO FISHER) 136

AVERA PHARMACEUTICALS 137

BAXTER HEALTHCARE 137

BAYER SCHERING PHARMA 138

BELLUS HEALTH 138

BIOFUTURA 139

BIOMERIEUX 139

BIOVAIL 140

BOEHRINGER INGELHEIM 140

BRACCO 140

BRAINCELLS, INC. 140

BRISTOL MYERS SQUIBB 141

CELLZOME 141

CEREGENE 142

COGNITION PHARMACEUTICALS LLC 142

COGNITION THERAPEUTICS 142

COLUCID PHARMACEUTICALS 143

COMENTIS 143

CORTEX PHARMACEUTICALS 144

C2N DIAGNOSTICS 144

CYTOS BIOTECHNOLOGY 145

DAIICHI SANKYO 145

DEBIOPHARM 146

DURECT 146

EISAI 146

ELAN 147

ELI LILLY 147

ENVIVO PHARMACEUTICALS 148

ESTEVE 148

EVOTEC 149

EXONHIT THERAPEUTICS 149

FOREST LABORATORIES 150

GALANTOS PHARMA 150

GALENEA 151

GE HEALTHCARE 151

GLAXOSMITH KLINE 152

HELICON THERAPEUTICS 152

INTELLECT NEUROSCIENCES 153

INTRA-CELLULAR THERAPIES 153

INVERNESS MEDICAL INNOVATIONS 154

IPSEN 154

JOHNSON & JOHNSON 155

KEYNEUROTEK 155

LEXICON PHARMACEUTICALS 155

LINK MEDICINE 156

LUNDBECK 156

MEDIVATION 157

MEMORY PHARMACEUTICALS 157

MERCK 158

MERCKSERONO 158

MERZ PHARMA 158

MITHRIDION 159

MITSUBISHI TANABE 159

MORPHOSYS 160

MP BIOMEDICALS 161

NEUREN PHARMACEUTICALS 161

NEUROPTIX 162

NEUROSEARCH 163

NEURO-HITECH 163

NEWRON PHARMACEUTICALS 163

NOSCIRA SA 164

NOVARTIS 165

NYMOX 165

OLIGOMERIX 166

ORTHO-MCNEIL NEUROLOGICS 166

PFIZER 166

POWER3 MEDICAL PRODUCTS 167

PRANA BIOTECHNOLOGY 167

PROTEOTECH INC. 168

PSYCHOGENICS 168

ROCHE 168

SAMARITAN PHARMACEUTICALS 169

SANOFI-AVENTIS 170

SATORI PHARMACEUTICALS 170

SATORIS 170

SCIELE PHARMA 171

SIEMENS MEDICAL SOLUTIONS 171

SOLVAY 172

SUVEN LIFE SCIENCE 172

TAKEDA 173

TARGACEPT 173

TAURX THERAPEUTICS 173

TAUTATIS 174

TEIKOKU 175

TEVA PHARMACEUTICALS 175

TRANSTECH PHARMA 175

VOYAGER PHARMACEUTICAL / DURAMED 176

WATSON PHARMACEUTICALS 176

WYETH/PFIZER 177

To order this report:

Therapy Industry:

More Market Research Report


    CONTACT:
    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com